Atox Bio is a late-stage biotechnology company that develops novel immunomodulators for critically ill patients. The companys lead product, Reltecimod, is initially being developed to treat necrotizing soft-tissue infection (NSTI), a rare, life-threatening infection for which no therapy currently exists.

Atox Bio recently completed enrollment of the Reltecimod clinical composite endpoint study in necrotizing soft tissue infections study (ACCUTE), a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI. Results of the study are expected to be presented at a medical meeting in the first half of 2020. The companys previous phase 2 study of Reltecimod in NSTI demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple endpoints.

Reltecimod was granted fast track and orphan drug designations for NSTI by the FDA and orphan medicinal product designation for NSTI by the European Commission. Development of Reltecimod is supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA).